Helping Patients Understand Secondary Cancer Risk
Patients who receive certain cancer treatments are at greater risk of secondary malignancies and must be educated accordingly.
FDA Approves Tislelizumab Combo for Advanced ESCC
The FDA approved tislelizumab-jsgr (Tevimbra) with platinum chemotherapy as a first-line treatment for adults with PD-L1-positive, unresectable or metastatic esophageal squamous cell carcinoma.
Hidden Cancer Risks of LA Wildfires
Hazards of the LA wildfires necessitate awareness that first responders and those central to the fires may be at risk for developing cancer.
OH2 Shows Safety and Anticancer Response with HX008 for Advanced Sarcoma
Preliminary findings suggest that OH2 monotherapy is safe, with promising responses observed when combined with HX008 in locally advanced or metastatic sarcoma.
Neoadjuvant Pembrolizumab Gets FDA Priority Review in Resectable HNSCC
Nivolumab/Ipilimumab Recieves FDA sBLA for Unresectable/Metastatic CRC
The FDA is conducting a priority review of nivolumab plus ipilimumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer.
Rucaparib Data Show Need for Further BRCA+ Ovarian Cancer Research
For patients with relapsed BRCA-mutated ovarian carcinoma, rucaparib produced a median OS of 19.4 months vs 25.4 months with chemotherapy in new findings.
Petosemtamab/Pembrolizumab Receives FDA Breakthrough Designation for PD-L1+ HNSCC
The FDA granted petosemtamab plus pembrolizumab breakthrough therapy status for PD-L1–positive recurrent/metastatic head and neck squamous cell carcinoma.
Cilta-Cel Associated With Higher HRQOL for Lenalidomide-Refractory MM
Median time to sustained worsening of symptoms was 23.7 months with cilta-cel, compared with 18.9 months with SOC.
SIGX1094 Receives FDA Fast Track Designation in Diffuse Gastric Cancer
The FDA granted SIGX1094 fast track status as a treatment option for diffuse gastric cancer.
Opinion: Oncology Nurses Can Ease the Burden of Time Toxicity in Cancer Care
Similar to financial toxicity, time toxicity can have a profound impact on a patient’s quality of life.
FDA Fast Track Designation Given to AUTX-703 in Relapsed/Refractory AML
AUTX-703, a novel, oral KAT2A/B degrader, has received fast track designation for use in relapsed/refractory AML.
NCCN Guidelines Update Includes HEPZATO KIT for Uveal Melanoma
Updates to the NCCN guidelines recommend HEPZATO KIT for use in hepatic-dominant uveal melanoma as a Category 2A treatment option.
FDA Grants Fast Track Designation to RZ-001 for HCC
The FDA has given RZ-001 fast track designation for HCC after demonstrating therapeutic activity in preclinical studies.
Perioperative FLOT Improves Survival in Resectable Esophageal Carcinoma
Perioperative chemotherapy improved survival compared with preoperative chemoradiotherapy in managing esophageal cancer.
Real-World Data Back First-Line Avelumab and Axitinib in Advanced RCC
Avelumab in combination with axitinib was found effective and safe as frontline treatment for advanced RCC in real-world findings.
NCCN Guideline Updates on ctDNA Stance in MCC and Colon, Rectal Cancer
The NCCN updated its guidelines to clarify the role of ctDNA as a biomarker for recurrence risk in colon and rectal cancer and for disease monitoring in Merkel cell carcinoma.
Tivozanib Combo Yields Similar PROs to Monotherapy in Advanced Clear Cell RCC
Patient-reported outcomes were consistent between patients with RCC using tivozanib/nivolumab and tivozanib monotherapy according to study findings.
T-DM1 Further Improves DFS and OS vs Trastuzumab in HER2-Positive Early Breast Cancer
T-DM1 reduced risk of invasive disease events and death compared with trastuzumab in HER2-positive early breast cancer with residual invasive disease after neoadjuvant therapy.
Immune Checkpoint Inhibitors May Increase Psoriasis Risk in Patients With Cancer
Immune checkpoint inhibitors for patients with cancer may be associated with an increased risk for psoriasis when compared with chemotherapy, monoclonal antibodies, and protease inhibitors.
Proactive Onco-Coaching Linked to Higher OS in mRCC
Proactive onco-coaching did not improve QOL but was associated with improved OS in patients with metastatic renal cell carcinoma receiving TKIs and ICIs.
Olanzapine May Address AEs From TKIs for Kidney and Other Cancers
Patients treated with tyrosine kinase inhibitors received olanzapine to address adverse effects including nausea/vomiting, anorexia, insomnia, and weight loss.
KN026-Docetaxel Combo Shows Efficacy, Safety in HER2+ Metastatic Breast Cancer
Patients with recurrent/metastatic HER2-positive breast cancer experienced durable response and manageable safety from KN026-docetaxel combination therapy.
Positive Responses to Liso-Cel Observed in Relapsed/Refractory Marginal Zone Lymphoma
Lisocabtagene maraleucel demonstrated a statistically significant overall response rate in adults with relapsed/refractory marginal zone lymphoma.
Cabozantinib Combo Maintains PFS for Advanced RCC at Follow-Up
New results uphold previous findings regarding the efficacy of cabozantinib, nivolumab, and ipilumumab arm for advanced renal cell carcinoma.
Nivolumab Plus Cabozantinib Effective Long-Term for Advanced RCC
Patients with advanced RCC who were treated with nivolumab plus cabozantinib had a median PFS of 16.4 months compared with 8.3 months from sunitinib alone.
High PSA Levels Before HIFU May Increase Recurrence Risk in Intermediate-Risk Prostate Cancer
Men with intermediate-risk prostate cancer and high PSA levels before HIFU treatment had a greater risk of both overall recurrence and treatment failure.
Enfortumab Vedotin and Pembrolizumab Effective in Treating Primary UTUC Lesions
Enfortumab vedotin alone and in combination with pembrolizumab showed promise in patients with upper tract urothelial carcinoma, particularly those ineligible for standard chemotherapy.
Real-World Data Support Enfortumab Vedotin for Urothelial Carcinoma Treatment
Real-world data demonstrate significant outcome improvements with enfortumab vedotin in patients with unresectable or metastatic urothelial carcinoma.
Darolutamide-ADT Combination Lengthens rPFS in mHSPC Regardless of Disease Volume
Patients with metastatic hormone-sensitive prostate cancer experienced increase rPFS and other efficacy end points with darolutamide plus ADT.
Nurses Lead Toxicity Monitoring in Indolent Lymphoma Care
Osimertinib/Chemo Boosts Survival in Frontline EGFR+ NSCLC
Lutetium Lu 177 Dotatate Brings Partial Response in Metastatic BP-NETs
Safety Management With Amivantamab Plus Lazertinib in NSCLC
